Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Phase 2
2(33.3%)
6Total
Phase 1(4)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT05202379Phase 1Completed

CC-42344 Safety Study in Healthy Participants

Role: lead

NCT07198139Phase 1Recruiting

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain Virus

Role: lead

NCT05977140Phase 1Completed

CDI-988 Safety Study in Healthy Participants

Role: lead

NCT06160531Phase 2Completed

Influenza Viral Challenge Study of CC-42344 in Healthy Participants

Role: lead

NCT03501550Phase 2Completed

Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)

Role: lead

NCT02760758Phase 1Completed

A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects

Role: lead

All 6 trials loaded